Pancreatic Cancer Research

ResearcherDartmouth CollegeActive in the last 2 years

Murray Korc

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-1566-0899; OpenAlex author ID A5052428479; NIH RePORTER profile ID 1891585. Sources: OpenAlex.

Their work

Papers
66 (first author 9, last author 24)
Trials
0
Grants
2
Labs led
4
Collaborators
138
Papers, trials and grants by year

2011: 8 papers · 2012: 7 papers, 1 grant · 2013: 4 papers · 2014: 12 papers · 2015: 4 papers · 2016: 10 papers · 2017: 6 papers · 2018: 7 papers, 1 grant · 2019: 1 paper · 2020: 1 paper · 2021: 2 papers · 2022: none · 2023: 1 paper · 2024: 1 paper · 2025: 2 papers

Papers 50 of 66

  1. Improved survival in pancreatic ductal adenocarcinoma: Exciting promise of multimodal management strategies. Co-author DOI 10.1016/j.canlet.2025.217828↗
  2. Editor's Note: Thioredoxin Is Downstream of Smad7 in a Pathway That Promotes Growth and Suppresses Cisplatin-Induced Apoptosis in Pancreatic Cancer. Last author DOI 10.1158/0008-5472.can-25-4286↗
  3. Bidirectional relationship between acute pancreatitis and pancreatic cancer. Co-author DOI 10.1097/mog.0000000000001051↗
  4. Heparin Prowess: Favorable Vascular-Immune Reprogramming in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-23-0346↗
  5. Trials and tribulations of pancreatic cancer immunotherapy. First author DOI 10.1016/j.canlet.2021.01.031↗
  6. The Current Treatment Paradigm for Pancreatic Ductal Adenocarcinoma and Barriers to Therapeutic Efficacy. Co-author DOI 10.3389/fonc.2021.688377↗
  7. FGFR4 Inhibitor BLU9931 Attenuates Pancreatic Cancer Cell Proliferation and Invasion While Inducing Senescence: Evidence for Senolytic Therapy Potential in Pan… Co-author DOI 10.3390/cancers12102976↗
  8. Pathogenesis of Pancreatic Cancer-Related Diabetes Mellitus: Quo Vadis? Co-author DOI 10.1097/mpa.0000000000001300↗
  9. Biomimetic and enzyme-responsive dynamic hydrogels for studying cell-matrix interactions in pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.biomaterials.2018.01.012↗
  10. Designer hydrogels: Shedding light on the physical chemistry of the pancreatic cancer microenvironment. First author DOI 10.1016/j.canlet.2018.08.008↗
  11. Diabetes Mellitus and Obesity as Risk Factors for Pancreatic Cancer. Co-author DOI 10.1016/j.jand.2017.07.005↗
  12. Beyond Kras: MYC Rules in Pancreatic Cancer Co-author DOI 10.1016/j.jcmgh.2018.04.009↗
  13. Safety and Efficacy of AAV Retrograde Pancreatic Ductal Gene Delivery in Normal and Pancreatic Cancer Mice. Co-author DOI 10.1016/j.omtm.2017.09.006↗
  14. The Interface of Pancreatic Cancer With Diabetes, Obesity, and Inflammation: Research Gaps and Opportunities: Summary of a National Institute of Diabetes and D… Co-author DOI 10.1097/mpa.0000000000001037↗
  15. Evaluation of a Mixed Meal Test for Diagnosis and Characterization of PancrEaTogEniC DiabeTes Secondary to Pancreatic Cancer and Chronic Pancreatitis: Rational… Co-author DOI 10.1097/mpa.0000000000001168↗
  16. Plasma microRNAs as biomarkers of pancreatic cancer risk in a prospective cohort study. Last author DOI 10.1002/ijc.30790↗
  17. Tobacco and alcohol as risk factors for pancreatic cancer. Co-author DOI 10.1016/j.bpg.2017.09.001↗
  18. Pancreatic cancer: Stroma and its current and emerging targeted therapies. Last author DOI 10.1016/j.canlet.2016.12.035↗
  19. A microRNA signature in circulating exosomes is superior to exosomal glypican-1 levels for diagnosing pancreatic cancer. Last author DOI 10.1016/j.canlet.2017.02.019↗
  20. Informative Patterns of Health-Care Utilization Prior to the Diagnosis of Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1093/aje/kwx168↗
  21. Diabetes, Pancreatogenic Diabetes, and Pancreatic Cancer. First author DOI 10.2337/db16-1477↗
  22. MicroRNA Expression in a Readily Accessible Common Hepatic Artery Lymph Node Predicts Time to Pancreatic Cancer Recurrence Postresection. Last author DOI 10.1007/s11605-016-3208-x↗
  23. Overview of pre-clinical and clinical studies targeting angiogenesis in pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.canlet.2015.11.047↗
  24. Combined targeting of TGF-β, EGFR and HER2 suppresses lymphangiogenesis and metastasis in a pancreatic cancer model. Last author DOI 10.1016/j.canlet.2016.05.037↗
  25. Sugar-Coated Proteins Pave the Way to Improving Pancreatic Cancer Diagnosis. Co-author DOI 10.1016/j.jcmgh.2016.01.001↗
  26. Type 3c (pancreatogenic) diabetes mellitus secondary to chronic pancreatitis and pancreatic cancer. Co-author DOI 10.1016/s2468-1253(16)30106-6↗
  27. Pancreatic cancer. First author DOI 10.1038/nrdp.2016.22↗
  28. Metastatic Pancreatic Adenocarcinoma After Total Pancreatectomy Islet Autotransplantation for Chronic Pancreatitis. Co-author DOI 10.1111/ajt.13851↗
  29. Regulation of HIF1α under Hypoxia by APE1/Ref-1 Impacts CA9 Expression: Dual Targeting in Patient-Derived 3D Pancreatic Cancer Models. Co-author DOI 10.1158/1535-7163.mct-16-0253↗
  30. Novel role of miR-29a in pancreatic cancer autophagy and its therapeutic potential. Co-author DOI 10.18632/oncotarget.11928↗
  31. Angiogenic gene signature in human pancreatic cancer correlates with TGF-beta and inflammatory transcriptomes. Last author DOI 10.18632/oncotarget.6345↗
  32. Integrated stress response is critical for gemcitabine resistance in pancreatic ductal adenocarcinoma. Last author DOI 10.1038/cddis.2015.264↗
  33. Pathophysiological role of microRNA-29 in pancreatic cancer stroma. Co-author DOI 10.1038/srep11450↗
  34. Pancreatic cancer-associated diabetes is an "exosomopathy". Co-author DOI 10.1158/1078-0432.ccr-14-2990↗
  35. TCGA data and patient-derived orthotopic xenografts highlight pancreatic cancer-associated angiogenesis. Last author DOI 10.18632/oncotarget.3233↗
  36. Nestin delineates pancreatic cancer stem cells in metastatic foci of NOD/Shi-scid IL2Rγ(null) (NOG) mice. Co-author DOI 10.1016/j.ajpath.2013.11.014↗
  37. Thiol-ene hydrogels as desmoplasia-mimetic matrices for modeling pancreatic cancer cell growth, invasion, and drug resistance. Co-author DOI 10.1016/j.biomaterials.2014.08.014↗
  38. Pancreatic cancer stroma: friend or foe? First author DOI 10.1016/j.ccr.2014.05.026↗
  39. Highly specific plasmonic biosensors for ultrasensitive microRNA detection in plasma from pancreatic cancer patients. Co-author DOI 10.1021/nl503220s↗
  40. A pilot study to develop a diagnostic test for pancreatic ductal adenocarcinoma based on differential expression of select miRNA in plasma and bile. Last author DOI 10.1038/ajg.2014.331↗
  41. Epithelial splicing regulatory protein 1 is a favorable prognostic factor in pancreatic cancer that attenuates pancreatic metastases. Co-author DOI 10.1038/onc.2013.392↗
  42. microRNA-10b enhances pancreatic cancer cell invasion by suppressing TIP30 expression and promoting EGF and TGF-β actions. Last author DOI 10.1038/onc.2013.405↗
  43. p38 MAPK in pancreatic cancer: finding a protective needle in the haystack. Co-author DOI 10.1158/1078-0432.ccr-14-1543↗
  44. Selective inhibition of pancreatic ductal adenocarcinoma cell growth by the mitotic MPS1 kinase inhibitor NMS-P715. Last author DOI 10.1158/1535-7163.mct-13-0324↗
  45. Pancreatic cancer-associated retinoblastoma 1 dysfunction enables TGF-β to promote proliferation. Last author DOI 10.1172/jci71526↗
  46. DUSP1 is a novel target for enhancing pancreatic cancer cell sensitivity to gemcitabine. Last author DOI 10.1371/journal.pone.0084982↗
  47. Critical role of NF-κB in pancreatic cancer. Co-author DOI 10.18632/oncotarget.2624↗
  48. Activated K-Ras and INK4a/Arf deficiency promote aggressiveness of pancreatic cancer by induction of EMT consistent with cancer stem cell phenotype. Co-author DOI 10.1002/jcp.24162↗
  49. A method for conducting highly sensitive microRNA in situ hybridization and immunohistochemical analysis in pancreatic cancer. First author DOI 10.1007/978-1-62703-287-2_4↗
  50. Molecular imaging in pancreatic cancer--a roadmap for therapeutic decisions. Last author DOI 10.1016/j.canlet.2013.08.008↗

Grants 2

  1. Dysregulation of TGF Beta Action Pancreatic Cancer R01CA075059↗
  2. Dysregulation of TGF Beta Action Pancreatic Cancer R37CA075059↗

Closest collaborators

The 25 strongest of 138 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jesse Gore · 12 shared papers, 2013–2016 · strength 0.77
  2. Min Li · 1 shared paper, 2025 · strength 0.54
  3. Kelly E. Craven · 6 shared papers, 2014–2016 · strength 0.42
  4. Chien‐Chi Lin · 3 shared papers, 2014–2018 · strength 0.37
  5. Christie Y. Jeon · 2 shared papers, 2017–2024 · strength 0.37
  6. Dana K. Andersen · 6 shared papers, 2013–2018 · strength 0.36
  7. Jorg H. Kleeff · 2 shared papers, 2016–2025 · strength 0.36
  8. Daniel R. Principe · 2 shared papers, 2021 · strength 0.33
  9. Ajay Nmn Rana · 2 shared papers, 2021 · strength 0.33
  10. Hidayatullah G. Munshi · 2 shared papers, 2021 · strength 0.33
  11. N Arnold · 1 shared paper, 2025 · strength 0.30
  12. Markus Wolfgang Büchler · 1 shared paper, 2025 · strength 0.30
  13. Helmut Friess · 1 shared paper, 2025 · strength 0.30
  14. Stuart Sherman · 5 shared papers, 2014–2017 · strength 0.30
  15. Jason J. Kwon · 4 shared papers, 2015–2018 · strength 0.28
  16. Janaiah Kota · 4 shared papers, 2015–2018 · strength 0.28
  17. Stephen Jacob Pandol · 4 shared papers, 2016–2018 · strength 0.28
  18. Anna Evans Phillips · 1 shared paper, 2024 · strength 0.28
  19. Richard A. Kozarek · 1 shared paper, 2024 · strength 0.28
  20. Toshiyuki Ishiwata · 5 shared papers, 2011–2020 · strength 0.27
  21. Aida Habtezion · 4 shared papers, 2016–2018 · strength 0.25
  22. Maxim S. Petrov · 3 shared papers, 2017–2018 · strength 0.23
  23. Gregory A. Coté · 4 shared papers, 2014–2017 · strength 0.22
  24. Guido Eibl · 3 shared papers, 2017–2018 · strength 0.21
  25. Mark Goodarzi · 3 shared papers, 2016–2018 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.